Calcium channel blockers(continued)
▶Antifungals, azoles(itraconazole, ketoconazole, voriconazole)are
predicted to increase the exposure tocalcium channel blockers
(diltiazem, verapamil).rStudy
▶Antifungals, azoles(posaconazole)are predicted to increase the
exposure tocalcium channel blockers(diltiazem, verapamil).
oTheoretical
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure toantifungals, azoles(isavuconazole).
oTheoretical
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure toantihistamines, non-sedating
(mizolastine).rTheoretical
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure toantihistamines, non-sedating
(rupatadine). Avoid.oStudy
▶Antimalarials(mefloquine)are predicted to increase the risk of
bradycardia when given withcalcium channel blockers.r
Theoretical
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the concentration ofantimalarials(piperaquine).
rTheoretical
▶Verapamilis predicted to increase the exposure toapixaban.
oTheoretical
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure toaprepitantandaprepitantis predicted
to increase the exposure tocalcium channel blockers(diltiazem,
verapamil).oStudy
▶Aprepitantis predicted to increase the exposure tocalcium
channel blockers(amlodipine, felodipine, lacidipine,
lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and
adjust dose.oStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure toaxitinib.oTheoretical
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tobedaquiline. Avoid prolonged use.
nTheoretical
▶Diltiazemis predicted to increase the risk of cardiodepression
when given withbeta blockers, non-selective.rStudy→
Also seeTABLE 6p. 848→Also seeTABLE 8p. 848
▶Intravenousverapamilincreases the risk of cardiovascular
side-effects when given withbeta blockers, non-selective.
Avoid.rStudy→Also seeTABLE 6p. 848→Also seeTABLE 8
p. 848
▶Oralverapamilincreases the risk of cardiovascular side-effects
when given withbeta blockers, non-selective.rStudy→
Also seeTABLE 6p. 848→Also seeTABLE 8p. 848
▶Diltiazemis predicted to increase the risk of cardiodepression
when given withbeta blockers, selective.rStudy→Also see
TABLE 6p. 848→Also seeTABLE 8p. 848
▶Intravenousverapamilincreases the risk of cardiovascular
side-effects when given withbeta blockers, selective. Avoid.
rStudy→Also seeTABLE 6p. 848→Also seeTABLE 8p. 848
▶Oralverapamilincreases the risk of cardiovascular side-effects
when given withbeta blockers, selective.rStudy→Also see
TABLE 6p. 848→Also seeTABLE 8p. 848
▶Bosentanis predicted to decrease the exposure tocalcium
channel blockers(amlodipine, felodipine, lacidipine,
lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and
adjust dose.oTheoretical
▶Bosentanis predicted to decrease the exposure tocalcium
channel blockers(diltiazem, verapamil).oTheoretical
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tobosutinib. Avoid or adjust dose.
rTheoretical
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tobuspirone. Use with caution and
adjust dose.oStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tocabozantinib.oTheoretical
▶Calcium channel blockers(diltiazem)are predicted to increase
the exposure tocalcium channel blockers(amlodipine). Monitor
and adjust dose.oStudy→Also seeTABLE 8p. 848
▶Calcium channel blockers(verapamil)are predicted to increase
the exposure tocalcium channel blockers(amlodipine,felodipine, lacidipine, lercanidipine, nicardipine, nifedipine,
nimodipine). Monitor and adjust dose.oStudy→Also
seeTABLE 8p. 848
▶Calcium channel blockers(diltiazem)are predicted to increase
the exposure tocalcium channel blockers(felodipine, lacidipine,
lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and
adjust dose.oStudy→Also seeTABLE 8p. 848
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure toceritinib.oTheoretical
▶Calcium channel blockers(diltiazem, nicardipine, verapamil)
increase the concentration ofciclosporin.rStudy
▶Ciclosporinmoderately increases the exposure tolercanidipine.
Use with caution or avoid.rStudy
▶Cobicistatis predicted to increase the exposure tocalcium
channel blockers(amlodipine, felodipine, lacidipine, nicardipine,
nifedipine, nimodipine). Monitor and adjust dose.o
Study
▶Cobicistatis predicted to increase the exposure tocalcium
channel blockers(diltiazem, verapamil).rStudy
▶Cobicistatis predicted to markedly increase the exposure to
lercanidipine. Avoid.rStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tocobimetinib.rTheoretical
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tocolchicine. Adjustcolchicinedose
with moderate inhibitors of CYP3A4.rStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure tocorticosteroids(methylprednisolone).
Monitor and adjust dose.oStudy
▶Crizotinibis predicted to increase the exposure tocalcium
channel blockers(amlodipine, felodipine, lacidipine,
lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and
adjust dose.oStudy
▶Verapamilincreases the exposure todabigatran. Adjust
dabigatrandose.rStudy
▶Intravenousdantrolenepotentially increases the risk of acute
hyperkalaemia and cardiovascular collapse when given with
calcium channel blockers(diltiazem, verapamil). Avoid.r
Anecdotal
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
slightly increase the exposure todarifenacin.oStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure todasatinib.rStudy
▶Calcium channel blockers(diltiazem, verapamil)increase the
concentration ofdigoxin. Monitor and adjust dose.r
Study→Also seeTABLE 6p. 848
▶Calcium channel blockers(diltiazem, verapamil)increase the risk
of QT-prolongation when given withdomperidone. Avoid.
rStudy
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure todopamine receptor agonists
(bromocriptine).rTheoretical→Also seeTABLE 8p. 848
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the concentration ofdopamine receptor agonists
(cabergoline).oAnecdotal→Also seeTABLE 8p. 848
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
moderately increase the exposure todutasteride.nStudy
▶Verapamilis predicted to slightly increase the exposure to
edoxaban.rTheoretical
▶Efavirenzis predicted to decrease the exposure tocalcium
channel blockers(amlodipine, felodipine, lacidipine,
lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and
adjust dose.oTheoretical
▶Efavirenzis predicted to decrease the exposure tocalcium
channel blockers(diltiazem, verapamil).oTheoretical
▶Calcium channel blockers(diltiazem, verapamil)are predicted to
increase the exposure toeliglustat. Avoid or adjust dose—
consult product literature.rStudy
▶Enzalutamideis predicted to decrease the exposure tocalcium
channel blockers(amlodipine, felodipine, lacidipine,
lercanidipine, nicardipine, nifedipine, nimodipine). Monitor and
adjust dose.oStudy
▶Enzalutamideis predicted to decrease the exposure tocalcium
channel blockers(diltiazem, verapamil).rStudy890 Calcium channel blockers—Calcium channel blockers BNFC 2018 – 2019
Interactions|Appendix 1A1